Clinical Trial

A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery

Completed
View on ClinicalTrials.gov →
Summary
This is a multicenter, observational cohort study in China with both primary prospective data collection and retrospective collection of prior treatment information from medical records, which enrolls and follows patients who are newly diagnosed with unresectable stage IIIB/IIIC/IV Non-Small-Cell Lung Cancer (NSCLC) in the selected sites. This study aims to describe the clinical practice and long-term survival benefits of patients newly diagnosed with unresectable stage IIIB/IIIC/IV NSCLC. The study also seeks to explore the condition of biomarker tests utilization, and to assess potential economic impact on patients in the real world. The safety related events will also be summarized in this study.
Protocol Amendment History 6 changes
critical Trial completed 2026-08-14
notable Enrollment reduced: 1200 -> 901 participants 2026-08-14
notable Primary completion moved earlier: 2026-11-06 -> 2026-03-18 2026-08-14
minor Completion moved earlier: 2026-11-06 -> 2026-03-18 2026-08-14
notable Primary completion pushed: 2026-09-21 -> 2026-11-06 2026-04-14
minor Completion pushed: 2026-09-21 -> 2026-11-06 2026-04-14
Trial Details
NCT Number NCT05872763
Lead Sponsor Hoffmann-La Roche
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 901 participants
Start Date 2023-08-11
Primary Completion 2026-03-18 (estimated)
Study Completion 2026-03-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-13